mAb TMDD Platform Model
Indication: Monoclonal Antibodies
Peripheral receptor occupancy (piPKRO) model for monoclonal antibodies. Simulates TMDD with tissue distribution, showing how peripheral target expression affects local drug depletion.
Drug Overview
Clinical Context
- Molecular Target
- Various
- Drug Class
- mAb
- Therapeutic Area
- Platform
- Indication
- Monoclonal Antibodies
- Route of Administration
- IV/SC
Model Information
- Model Type
- 2-compartment + TMDD (QSS/QE)
- Category
- PK/PD
This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.
Pharmacokinetic Parameters
PK Parameters
| Parameter | Value |
|---|---|
| Q | 0.5-1 L/day |
| Vc | 3-5 L |
| Vp | 2-3 L |
| t half | 14-21 days |
| CL linear | 0.2-0.5 L/day |
Additional Parameters
| Parameter | Value |
|---|---|
| Kd | 0.01-10 nM |
| kon | 1e5 M⁻¹s⁻¹ |
| Rmax | 1-100 nM |
| kint | 0.1-1 day⁻¹ |
| koff | 1e-4 s⁻¹ |
| ksyn | varies by target |
Parameters sourced from published population pharmacokinetic models. Values represent typical population estimates; individual patient parameters may vary.
About This Simulator
This interactive pharmacokinetic simulator for mAb TMDD Platform Model allows you to explore concentration-time profiles under different dosing scenarios. The underlying PK/PD model characterizes the pharmacokinetics of this mab following iv/sc administration.
Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.
Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.
Frequently Asked Questions
What is the mAb TMDD Platform Model PK simulator?
This is a free, interactive pharmacokinetic simulator for mAb TMDD Platform Model used in Monoclonal Antibodies. It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.
What drug class does mAb TMDD Platform Model belong to?
mAb TMDD Platform Model is classified as a mAb that targets Various. It is used in the Platform therapeutic area.
What route of administration does this model simulate?
This simulator models IV/SC administration of mAb TMDD Platform Model. The pharmacokinetic parameters (absorption rate, bioavailability, volume of distribution) are specific to this route.
What type of PK model is used?
This simulator uses a PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.
Is this simulator free to use?
Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.
Can I use this for clinical dosing decisions?
No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.
What is the half-life of mAb TMDD Platform Model?
Based on the published model parameters, the elimination half-life of mAb TMDD Platform Model is approximately 14-21 days. Note that half-life can vary based on patient-specific factors such as body weight, organ function, and genetic polymorphisms.
What is the clearance of mAb TMDD Platform Model?
The clearance (CL) of mAb TMDD Platform Model is approximately 0.2-0.5 L/day. Clearance represents the volume of plasma from which drug is completely removed per unit time and is a key determinant of drug exposure and steady-state concentrations.
Related Simulators
Xolair (Omalizumab) PK Simulator
Moderate-to-severe allergic asthma
Tremfya (Guselkumab) PK Simulator
Plaque psoriasis
Tecentriq (Atezolizumab) PK Simulator
Non-small cell lung cancer
Stelara (Ustekinumab) PK Simulator
Plaque psoriasis
Skyrizi (Risankizumab) PK Simulator
Plaque psoriasis
Prolia (Denosumab) PK Simulator
Postmenopausal osteoporosis
Ready to Simulate?
Launch the mAb TMDD Platform Model simulator to explore dosing scenarios and pharmacokinetic profiles interactively.
🚀 Launch SimulatorComments
⚠️ Disclaimer
This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.
Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community